Fig. 1

Changes of radiography and tumor markers at different period of treatment. (A) Imaging examinations (CT or MRI scans) performed at baseline and at first, second, third evaluation (every 2 treatment cycles as one round of radiographic evaluation), showed approximately 23%, 31% and 32% decreases in sum of diameters of target lesions compared with baseline imaging. (B) CT scans performed at fourth evaluation when deveioping HPD to camrelizumab revealed the changes in ascites and pulmonary metastases, accompanied by rapidly increasing NSE and CA-125 levels. The red arrows indicate tumor lesions